tocilizumab
SpainDrugs containing this active substance
-
It is used to treat moderate to severe rheumatoid arthritis in adults, giant cell arteritis in adults, and systemic or polyarticular juvenile idiopathic arthritis in children and adolescents aged 12 years and older.
Form: solution for injection in pre-filled pen
Active substance Dosage tocilizumab 162 mg Manufacturer: Celltrion Healthcare Hungary Kft.
-
It is used to treat active rheumatoid arthritis in adults (moderate to severe or severe and progressive), giant cell arteritis in adults, and systemic or polyarticular juvenile idiopathic arthritis in children and adolescents.
Form: solution for injection in a pre-filled syringe
Active substance Dosage tocilizumab 162 mg Manufacturer: Celltrion Healthcare Hungary Kft.
-
It is used to treat active rheumatoid arthritis in adults, juvenile idiopathic arthritis (JIA and JIA polyarticular) in children aged 2 years and older, severe or potentially life-threatening cytokine release syndrome, and COVID-19 disease in adults requiring oxygen or mechanical ventilation.
Form: solution for infusion, concentrate
Active substance Dosage tocilizumab 20 mg/ml Manufacturer: Celltrion Healthcare Hungary Kft.
-
It is used to treat adults with active rheumatoid arthritis (moderate to severe or severe and progressive), adults with giant cell arteritis (inflammation of the arteries), and children or adolescents (12 years and older) with active systemic or polyarticular juvenile idiopathic arthritis.
Form: solution for injection in pre-filled pen
Active substance Dosage tocilizumab 162 mg Manufacturer: Roche Registration Gmbh
-
It is used to treat rheumatoid arthritis in adults, giant cell arteritis in adults, and systemic or polyarticular juvenile idiopathic arthritis in children and adolescents.
Form: solution for injection in a pre-filled syringe
Active substance Dosage tocilizumab 162 mg Manufacturer: Roche Registration Gmbh
-
It is used to treat active rheumatoid arthritis in adults, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA) in children aged 2 years and older, severe or potentially life-threatening cytokine release syndrome (CRS) in adults and children, and coronavirus disease 2019 (COVID-19) in adults requiring supplemental oxygen or mechanical ventilation.
Form: solution for injection
Active substance Dosage tocilizumab 20 mg Manufacturer: Roche Registration Gmbh
-
It is used to treat active rheumatoid arthritis in adults, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA) in children aged 2 years and older, severe or potentially life-threatening cytokine release syndrome (CRS) in adults and children, and coronavirus disease 2019 (COVID-19) in adults requiring oxygen or mechanical ventilation.
Form: solution for injection
Active substance Dosage tocilizumab 20 mg Manufacturer: Roche Registration Gmbh
-
It is used to treat active rheumatoid arthritis in adults (moderate to severe or severe and progressive), giant cell arteritis in adults, and systemic or polyarticular juvenile idiopathic arthritis in children and adolescents aged 12 years or older.
Form: solution for injection in pre-filled pen
Active substance Dosage tocilizumab 162 mg Manufacturer: Fresenius Kabi Deutschland Gmbh
-
It is used to treat rheumatoid arthritis (RA) in adults, giant cell arteritis (GCA) in adults, and systemic juvenile idiopathic arthritis (sJIA) or polyarticular juvenile idiopathic arthritis (pJIA) in children and adolescents.
Form: solution for injection in a pre-filled syringe
Active substance Dosage tocilizumab 162 mg Manufacturer: Fresenius Kabi Deutschland Gmbh
-
It is used to treat adults with moderate to severe active rheumatoid arthritis, adults with COVID-19 who require oxygen or mechanical ventilation, and individuals (adults and children aged 2 years and older) with severe or potentially life-threatening cytokine release syndrome. It is also used in children aged 2 years and older with systemic juvenile idiopathic arthritis (sJIA) or polyarticular juvenile idiopathic arthritis (pJIA).
Form: solution for infusion, concentrate
Active substance Dosage tocilizumab 20 mg Manufacturer: Fresenius Kabi Deutschland Gmbh